Skip to main
ZBH
ZBH logo

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 36 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 42%
Sell 6%
Strong Sell 3%

Bulls say

Zimmer Biomet Holdings is projected to achieve 2025 sales of $7.85 billion, reflecting a 4.0% year-over-year increase when excluding foreign exchange impacts, alongside an adjusted EPS of $8.23, indicating a growth of 2.9% year-over-year. Despite losing some global reconstructive market share, the company's strategic focus on new product launches in the knee and hip segments, particularly in their Persona portfolio and ROSA technology, is expected to bolster its market position and enhance revenue growth in high-potential areas. Additionally, the anticipated operational margin expansion from the ZimVie spin-off is likely to support Zimmer Biomet’s goal of averaging a 30 basis point increase in operational margin annually.

Bears say

The analysis indicates a negative outlook for Zimmer Biomet Holdings primarily due to anticipated revenue growth slowing to 2% or less, driven by underperforming ROSA robot sales and disappointing new product launches, leading to below-consensus earnings. Furthermore, the company faces significant headwinds from currency fluctuations and potential pricing pressures in the orthopedic implant market, with guidance for adjusted EPS falling short of consensus estimates. Additionally, risks related to slower orthopedic market growth, dilutive acquisitions, and new product performance add to the uncertainty surrounding the company's financial trajectory.

ZBH has been analyzed by 36 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 42% suggest Holding, 6% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Buy based on their latest research and market trends.

According to 36 analysts, ZBH has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.